Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 11
Submit an article Journal homepage
62
Views
16
CrossRef citations to date
0
Altmetric
Review

Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias

Joachim Brendel Aventis Pharma Deutschland GmbH, Medicinal Chemistry, G878, D-65926 Frankfurt/Main, Germany
&
Stefan Peukert Aventis Pharma Deutschland GmbH, Medicinal Chemistry, G878, D-65926 Frankfurt/Main, Germany
Pages 1589-1598 | Published online: 25 Feb 2005

Bibliography

  • KANNEL WB, WOLF PA, BENJAMIN EJ, LEVY D: Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am. Cardiol. (1998) 82:2N–9N.
  • GERLACH U: IKs channel blockers: potential antiarrhythmic agents. Drugs Fut. (2001) 26:473–484.
  • PRATT CM, MOYE LA: The cardiac arrhythmia suppression trial: background, interim results and implications. Am. J. Cardiol. (1990) 65(4):20B-29B.
  • WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet (1996) 348:7–12.
  • BRIL A: Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation. Carr. Opin. Pharmacol. (2002) 2(2):154–159.
  • •Concise review summarising some approaches currently being investigated for the treatment of atrial arrhythmia.
  • NATTEL S, HADJIS T, TALAJIC M: The treatment of atrial fibrillation. Drugs (1994) 48:345–371.
  • NISHIDA A, UEMURA H, OGURAT, FURUSAWA H, YABANA H, NAKAYA H: Inhibitory effects of azimilide on K+ currents in isolated guinea-pig cardiomyocytes. Jpn. Pharmacol. (2000) 82:1–12.
  • LI GR, FENG J, YUE L, CARRIER M, NATTEL S: Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ. Res. (1996) 78:689–696.
  • FENG J, WIBLE B, LI GR, WANG Z, NATTEL S: Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ. Res. (1997) 80:572–579.
  • AMOS GJ, WETTWER E, METZGER F, LI Q, HIMMEL HM, RAVENS U: Differences between outward currents of human atrial and subepicardial ventricular myocytes. Physiol. (Lond) (1996) 491:31–50.
  • FEDIDA D, WIBLE B, WANG Z et al.: Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ. Res. (1993) 73:210–216.
  • •First description of Kv1.5 in relation to IK, on human atria.
  • WANG Z, FERMINI B, NATTEL S: Sustained depolarisation-induced outward current in human atrial myocytes. Circ. Res. (1993) 73:1061–1076.
  • •First study to suggest IK. blockade as a new approach to the pharmacological therapy of atrial arrhythmia.
  • NATTEL S, YUE L, WANG Z: Cardiac ultrarapid delayed rectifiers. Cell Physiol. Biochem. (1999) 9:217–226.
  • ASHCROFT MA: Voltage gated K+ channels. In: Ion channels and disease. Academic Press, London (2000):97–123.
  • FENG J, XU D, WANG Z, NATTEL S: Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am. .1 Physiol. (1998) 275:H1717–H1725.
  • SCHAFFER P, PELZMANN B, BERNHART E, LANG P, LOKEBO JE, MACHLER H et al: Estimation of outward currents in isolated human atrial myocytes using inactivation time course analysis. Flingers Arch. Eur. j Physiol. (1998) 436:457–468.
  • NYGREN A, LEON LJ, GILES WR: Simulations of the human atrial action potential. Phil. Trans. R. Soc. Lond. A. (2001) 359:1111–1125.
  • NYGREN A, FISET C, FIREK L, CLARK JW, LINDBLAD DS, CLARK RB et al.: Mathematical model of an adult human atrial cell. Circ. Res. (1998) 82:63–81.
  • COURTEMANCHE M, RAMIREZ RJ, NATTEL S: Ionic targets for drug therapy and atrial fibrillation-induced electrical remodelling: insights from a mathematical model. Cardiovasc. Res. (1999) 42:477–489.
  • •Interesting theoretical analysis of how blockade of various ion channels influences the AP in normal and remodelled hearts.
  • WANG Z, FERMINI B, NATTEL S: Effectsof flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. Pharmacol Exp. Ther. (1995) 272:184–196.
  • FRANQUEZA L, VALENZUELA C, DELPON E, LONGOBARDO M, CABALLERO R, TAMARGO J: Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. Br: J. Pharmacol. (1998) 125:969–978.
  • GROSS GJ, CASTLE NA: Propafenone inhibition of human atrial myocyte repolarizing currents. J. MM. Cell. Cardiol. (1998) 30:783–793.
  • SEKI A, HAGIWARI N, KASANUKI H: Effects of propafenone on K currents in human atrial myocytes. Br. J. Pharmacol. (1999) 126:1153–1162.
  • KOBAYASHI S, REIEN Y, OGURA T, SAITO T, MASUDA Y, NAKAYA H: Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031. Eur. .1 Pharmacol (2001) 430:149–157.
  • STEIDL JV, YOOL AJ: Distinct mechanisms of block of Kv1.5 channels by tertiary and quaternary amine clofilium compounds. Biophysical Journal (2001) 81(5):2606–2613.
  • IFTINCA M, WALDRON GJ, TRIGGLE CR, COLE WC: State-dependent block of rabbit vascular smooth muscle delayed rectifier and Kv1.5 channels by inhibitors of cytochrome P450-dependent enzymes. J. Pharmacol. Exp. Ther. (2001) 296:718–728.
  • GONZALES T, LONGOBARDO M, CABALLERO R, DELPON E, TAMARGO J, VALENZUELA C: Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K+ channels. .1 Pharmacol. Exp. Ther. (2001) 296:573–583.
  • RAMPE D, MURAWSKY MK: Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin. Nau. Schmied. Arch. Pharmacol. (1997) 355:743–750.
  • RAMPE D, WIBLE B, FEDIDA D, DAGE RC BROWN AM: Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart. MM. Pharmacol. (1993) 44:642–648.
  • ZHANG X, ANDERSON JW, FEDIDA D: Characterization of nifedipine block of the human heart delayed rectifier, hKv1.5. J. Pharmacol. Exp. Ther. (1997) 281:1247–1256.
  • VALENZUELA C, DELPON E, FRANQUEZA L et al: Class III antiarrhythmic effects of zatebradine: time-, state-, use-, and voltage-dependent block of hKv1.5 channels. Circulation (1996) 94:562–570.
  • CHOI BK, CHOI JS, JEONG SW et al:Direct block by bisindolylmaleimide of rat Kv1.5 expressed in chinese hamster ovary cells. Pharmacol. Exp. Ther. (2000) 293(2):634–640.
  • DELPON E, VALENZUELA C, GAY P, FRANQUEZA L, SNYDERS DJ, TAMARGO J: Block of human cardiac Kv1.5 channels by loratadine: voltage-, time-and use-dependent block at concentrations above therapeutic levels. Cardiovasc. Res. (1997) 35:341–350.
  • LACERDA AE, ROY ML, LEWIS EW, RAMPE D: Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol (1997) 52(2):314–322.
  • YUE L, FENG J, LI GR, NATTEL S: Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. Physiol (1996) 496:647–662
  • COGHLAN MJ, CARROLL WA, GOLAPAKRISHNAN M: Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. (2001) 44(11):1–27.
  • MATSUDA T, SAITO T, ITOKAWA M et al.: Atrial selective prolongation by NIP-142 of refractory period and action potential duration in guinea-pig myocardium. fpn. Pharmacol (2001) 85\(Supp1.1):71.
  • NAGASAWA H, FUJIKI A, USUI M et al.:fpn. Circ. J. (1999) 63\(Suppl. 1):361P
  • NAGASAWA H, FUJIKI A, INOUE H, FUJIKURA N: fpn. Circ. J. (2000) 64\(Suppl. 1):606P
  • MATSUDA T, MASUMIYA H, TANAKA N et al.: Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sciences (2001) 68(17):2017–2024.
  • SEKI A, HAGIWARA N, KASUNAKI H: fpn. Electrocardiol (1999) 19:595P
  • SEKI A, HAGIWARA N, KASANUKI H: Effects of NIP-141 on K-currents in human atrial myocytes. Cardiovasc. Pharmacol (2002) 39:29–38.
  • NAGASAWA H, FUJIKI A, FUJIKURA N, MATSUDA T, YAMASHITA T, INOUE H: Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ. (2002) 66(2):185–191.
  • •Detailed investigation of the in vivo profile of a Kv1.5 blocker.
  • MATSUDA T, ISHIMARU S, SAITO T et al: Effect of NIP-142 on carbachol-induced myocardial action potential shortening and human GIRK1/4 channel current. fpn. Pharmacol (2002) 88\(Suppl. 1):260P
  • SCHNEIDER G, CLEMENT- CHOMIENNE 0 et al: Virtual screening for bioactive molecules by evolutionary de novo design. Angew. Chem., Int. Ed (2000) 39:4130–4133.
  • BACHMANN A, GUTCHER I, KOPP K et al.: Characterization of a novel Kv1.5 channel blocker in Xenopusoocytes, CHO cells, human and rat cardiomyocytes. Neu. Schnned. Arch. Pharmacol (2001) 364:472–478.
  • KNOBLOCH K, BRENDEL J, PEUKERT S, ROSENSTEIN B, BUSCH AE, WIRTH KJ: Electrophysiological and antiarrhythmic effects of the novel II(m. blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Neu. Schmied. Arch. Pharmacol (2002) 366:482–487.
  • •Detailed investigation of the in vivo profile of Kv1.5 blockers.
  • TANHEHCO EJ: Potassium channel modulators as anti-inflammatory agents. Expert Opin. Ther: Patents. (2001) 11:1137–1145.
  • NO AUTHORS LISTED: Astra Zeneca company presentation, Annual Business Review Presentation, December 3rd, London, UK (2001).

Websites

  • http://www.icagen.com/ prod_pre_clinical.html#atrial Icagen company World Wide Web site July 2 (2002).
  • http://www.cardiome.com/pdf/ Kv15_0ct15_2001.pdf Cardiome Pharma Corp. company World Wide Web site, Kv1.5 fact sheet October 15(2001).
  • http://www.cardiome.com/pdf/ RSD1235_v7_Feb_28_2001.pdf Cardiome Pharma Corp. company World Wide Web site, RSD1235 fact sheet December 24 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.